Zentalis Pharmaceuticals Inc

$51.65 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., formerly Zentalis Pharmaceuticals LLC., is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of cell lung cancer.

Stock Analysis

last close $50.99
1-mo return -2.6%
3-mo return -13.8%
avg daily vol. 352.64T
52-week high 62.79
52-week low 25.41
market cap. $2.3B
forward pe -
annual div. -
roe -175.8%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 85.3%
baraka

Subscribe now for daily local and international financial news

Subscribe